GIIANT PHARMA
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
GIIANT PHARMA
Industry:
Biopharma Biotechnology Health Care Life Science
Founded:
2014-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.giiant.com
Total Employee:
1+
Status:
Active
Contact:
(514) 825-9035
Total Funding:
15 M CAD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Enthera
Enthera is a biotech company whose mission is to find new therapeutic approaches to treat diabetes and gastrointestinal complication.
Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals is a clinical stage biotech company.
Priority Health
Priority Health is an award-winning health benefits company.
Current Advisors List
Board_member
2021-05-01
Board_member
2021-06-01
Current Employees Featured
Maxime Ranger Chief Executive Officer @ Giiant Pharma
Chief Executive Officer
2020-06-01
Elizabeth Kwong Co-Founder & Chief Development Officer @ Giiant Pharma
Co-Founder & Chief Development Officer
2011-12-01
Patrick Colin Chief Clinical Officer @ Giiant Pharma
Chief Clinical Officer
2021-01-01
Christophe Mellon Vice President @ Giiant Pharma
Vice President
2021-01-01
Founder
Investors List
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Seed Round - Giiant Pharma
AQC Capital
AQC Capital investment in Seed Round - Giiant Pharma
Theodorus III
Theodorus III investment in Seed Round - Giiant Pharma
Genesys Capital
Genesys Capital investment in Seed Round - Giiant Pharma
CQDM
CQDM investment in Seed Round - Giiant Pharma
Amplitude Venture Capital
Amplitude Venture Capital investment in Seed Round - Giiant Pharma
Anges Quebec
Anges Quebec investment in Seed Round - Giiant Pharma
Amorchem
Amorchem investment in Seed Round - Giiant Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-09 | Giiant Pharma Appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry |
Official Site Inspections
http://www.giiant.com Semrush global rank: 6.12 M Semrush visits lastest month: 1.33 K
- Host name: 47.119.180.107.host.secureserver.net
- IP address: 107.180.119.47
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Giiant Pharma"
about us - Giiant Pharma – The gut-restricted IBD …
Founded in 2010, Crystal Pharmatech is a technology-driven contract research organization, providing comprehensive solutions in solid-state research, crystallization development, pre-formulation studies and formulation …See details»
Giiant Pharma - Crunchbase Company Profile & Funding
Organization. Giiant Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Giiant is a …See details»
home - Giiant Pharma – The gut-restricted IBD solution
Giiant pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision delivery remains a central focus for the development of new drug therapeutics, …See details»
giiant pharma inc. | LinkedIn
Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various ...See details»
giiant pharma - Amorchem
Giiant pharma. Giiant Pharma Inc. (www.giiant.com) is a Montreal-based preclinical-stage biotech company developing gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of of inflammatory bowel …See details»
Giiant Pharma - Products, Competitors, Financials, Employees ...
Giiant Pharma's lead program, GT-2108, is designed to target moderate-to-severe ulcerative colitis with a colon-specific PDE4 inhibitor prodrug that is activated by the gut microbiota. It …See details»
Giiant Pharma Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Giiant Pharma Inc. of Notre-Dame-De-L'Île-Perrot, QC. Get the latest business insights from Dun & Bradstreet.See details»
Genesys Capital | Giiant Pharma Inc.
Giiant Pharma Inc. is a Montreal-based biotech company, founded by former Merck Frosst scientists, with the aim of developing orally-administered, gut-restricted anti-inflammatory …See details»
Giiant Pharma - 2025 Company Profile - Tracxn
Apr 26, 2025 Giiant Pharma - Developer of colon-specific anti-inflammatory therapy for ulcerative colitis. Raised a total funding of $12.2M over 2 rounds from 8 investors. Founded by …See details»
Giiant Pharma - Contacts, Employees, Board Members
Giiant Pharma is a preclinical-stage biotech company. Start Free Trial . Chrome ExtensionSee details»
Giiant Pharma - Biotech Careers
Giiant pharma inc. is a Montreal-based biotech company, founded by former Merck Frosst scientists, with the aim of developing orally-administered, gut-restricted anti-inflammatory …See details»
Giiant Pharma Inc. announced the closing of US$11M in Seed …
“giiant pharma is a perfect fit with Amplitude’s vision of creating, building, and growing world-class Canadian precision medicine companies. We’re convinced giiant has the talent and network to …See details»
Giiant Pharma - Overview, News & Similar companies - ZoomInfo
Jan 10, 2023 Who is Giiant Pharma. Giiant is a preclinical-stage biotech company that designs gut-restricted, tissue-specific, small molecule, drug therapeutics using its proprietary Precision …See details»
Giiant Pharma - VentureRadar
" giiant pharma Inc is a Montreal-based biotech company, founded by two former Merck Frosst scientists, and repeat entrepreneurs with a significant depth of expertise in the area of …See details»
Giiant Pharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Giiant Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, 11 news, Disease Domain:Immune System Diseases, Technology Platform:Small molecule drug, …See details»
Giiant Pharma Inc Announced the Closing of US$11m in Seed …
May 21, 2021 MONTREAL--(BUSINESS WIRE)--Giiant Pharma inc., a Montreal-based preclinical-stage biotech company, today announced the closing of US$11M (CAD$ 13.5M) …See details»
Giiant Pharma, Inc. (Giiant Pharma, Inc.) - 药物管线_专利_临床试 …
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit …See details»
Giiant Pharma — building the next precision GI medicine company
May 26, 2021 Last week, Giiant Pharma announced the close of a US $11M (CAD $13.5M) seed round. We’re excited to co-lead this financing with Genesys Capital to build a precision GI …See details»
Palisade Bio | Advancing Next-Generation Precision Therapies
Sep 6, 2023 Giiant Pharma (www.giiant.com), a preclinical-stage biotech company, designs gut-restricted small molecule, drug therapeutics with various biological targets in gastroenterology …See details»
Giiant Pharma Inc. strengthens its Board of Directors with the ...
Jun 17, 2021 MONTREAL–(BUSINESSWIRE)–Giiant Pharma Inc., a preclinical-stage biotech company developing gut-restricted drug therapeutics in gastroenterology, announced the …See details»